二四六图片大全 百度 (Celgene sales highlight Revlimid dependence ahead of patent ruling


(Reuters) - Celgene Corp’s depende【2014全年马会特码资料 】nce on its big-selling multiple myeloma drug Revlimid raised investo【鼠龙有数特来算拆一肖 】r concerns on Thursday as sales of its other medicines fell short of expectations. Celgene【跑狗诗全年记录 】 shares fell【四不像解玄机 】 5【买特马图片2020 】 percent after the company reported quarterly results in【七肖特码彩坛 】 whic【老奇人四字成语解特 】h Revlimid shored up profits. Industry analysts see room for 【2020东方心京每期自动更新ab面 】Revlimid to grow much further, with some estimating the drug will nearly double annual sales in coming

years. But investors may be hesitating as Celg【买马资料今晚2020 】ene faces a legal challenge that could cut its exclusive sales rights in Europe by a year or two. The European Patent Office hearing on a Revlimid patent that runs through 2024 is set for May 7. “Nobody seems to w【行踪隐蔽打一肖 】ant to buy the stock in front of May 7,” s【今天正版牛头报图片 】aid RBC Capital Markets analy【2020年第65期跑狗玄机图 】st Michael Yee. “Once【2017年今日马报结果 】 we get pas【神算子高清跑狗图香港 】t that, I【本港台报码室kj 】 think the stock rebounds.” Revlimid sales of $1.34 billion in the firs【123历史图库2o17全年彩图 】t quarter were in line with expectations and especially 【今天波色 】strong in the United States. Sales of the canc【2017新报跑狗高清图 】er drug Abra【精准三码资料大全 】xane, and newer medicines Pomalyst for m

ultiple myeloma and Otezla for psoriatic arthritis and psoriasis all fell short of forecasts. Invent

o【鬼六图库神算 】ry stocking, higher co-pays and demands by payers for larg【zlcom二四六天天好彩 】er Otezla rebates contributed to first quarter weakness, analysts said. The New Jersey-based com【第118期管家婆心水报 】pany said it now 【黑白跑狗图超清 】sees 2015 Revlimid sales at or above $5.7 billion, the high end of its prior forecast range. The drug accounts for about 60 percent of Celgene revenue

. Patients are using the treatment lo【香港商报彩经图 】nger to keep their cancer at bay, the company sa【香港三色彩票有限公司马上开 】id. In addition, U.S. and European regulators recently expanded approvals to allow its u【香港马会104期资料 】se in newly diagnosed multi【2020六开彩开奖结记录 】ple myeloma patients, which will drive growth. Cantor Fitzge【管家婆手机站论坛27355 】rald anal【皇家马会app 】yst Mara G【2020年马经精版料图片 】oldstein forecast Revlimid sales reaching $【赛尔号必中技能有哪些 】1【香港赛马会中特范围 】0 billion by 2020 if i【香港新版挂牌独家发布 】ts

duration of use and geogra【118图库彩图小赌经 】phic expansion continues to grow, along with approvals or new uses. &ld【跑狗图高清解释最新最快 】quo;It’s a hig【2020笫2期新版跑狗图 】h class problem to have,” she said of the company’s dependence 【南堡开发区急售二手房 】on Revlimid. She predicts Revlimid will declin【高清跑狗图最早最快更新跑狗图 】e as a percentage of profit “not because it’s declining, but because other products are growing. That’s a very positive dynamic.” Celgene said it anticipates “significant market share gains over coming mont

hs and years&【天空彩票网m.tkcp.cc 】rdquo; with reimbursements for newly d【2020年5组三中三资料 】iagnosed patients in Europe, and with a【六开彩网址是多少 】n expected appro【2018年3月5号新跑狗图 】val in Japan for such patients around the end of the year. The company is also conducting five late-stage trials of Revlimid in a

variety of lymphomas. “It’s always less risky to expand the opportunities for an existing drug tha【凌波微步解跑狗彩图 】n to invest in advancing a new【六合四不像图片高手 】 drug,”【天将图库 图库 彩库 香港开奖记录 】 Bernstein analyst Geoffrey Porges said. “They happen to have a great d

rug that still has a

lot of runway in fr【333397跑狗网 】ont of it.” Investors still have high hopes for future blockbuster sales of Celgene’s experimental drug for Crohn’s disease. The company is also collaborating with AstraZeneca to test Abraxane 【今期特马开什麽 波色表 】and other C

elgene products in combination【管家婆八肖2020官网 】 with experimental Astra drug

s that spur the immune system to fight can【小鱼网儿玄机2站开奖直播現场 】cer. Such partnerships “suggest there&rsq【东方心经2020新资料 】uo;s going to be a huge range【152期六开彩马报 】 of revenue opportunities for them five to 10 years from now,

” Porges said.

上一篇:
下一篇: